ACC 2022 Prof. Handberg shares and interprets the findings from the SuperWIN study. "We have the ability with this type of intervention to really impact multiple generations", she said.

ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.

ACC 2022 This randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.

ACC 2022 The SuperWIN study showed that an intervention of dietary education visits in the supermarket with feedback of their own purchasing data with or without training on online shopping improves adherence to the DASH diet after 3 months.

ACC 2022 A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we are going to be able to treat this disorder”, Nissen said.

ACC 2022 Although a reduction in sodium intake in HF patients did not result in a reduction of all-cause mortality of CV hospitalization compared to usual care, patient-centered outcomes were improved.

ACC 2022 What are the findings of the DIAMOND trial with the potassium binder patiromer in patients with HFrEF who were on RAASi therapy?

ACC 2022 Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

ACC 2022 The SODIUM-HF trial showed that a dietary intervention to reduce sodium intake did not reduce clinical events in ambulatory patients with HF. However, sodium reduction improved quality of live and NYHA class.

ACC 2022 An analysis showed that treatment with empagliflozin in patients with acute HF resulted in clinical benefit, regardless of symptomatic impairment at baseline, and improved symptoms, physical function and quality of life.

ACC 2022 Prof. Tita shares the results of the CHAP trial, which showed that treatment of mild chronic hypertension in pregnant women to a BP goal <140/90 mmHg reduces adverse pregnancy outcomes and does not impair fetal growth.

ACC 2022 Based on results from the SODIUM-HF trial, what can you tell your patients with heart failure when they take a small amount of salt and worry about harmful effects?